ArticleNeurocritical care2026
Neutrophil Extracellular Traps in Patients with Intracerebral Hemorrhage.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSpontaneous intracerebral hemorrhage (ICH) is a subtype of stroke frequently resulting in severe disability. Secondary mechanisms after ICH include neuroinflammation and development of perihematomal edema. Neutrophil extracellular traps (NETs) mediate infection defense and are involved in disease processes affecting the nervous system, including immunothrombosis and blood-brain barrier disruption. We aimed to assess NETs in ICH and their potential contribution to outcome measures.
methodsWe conducted a prospective, single-center cohort study recruiting patients with ICH within 24 h after symptom onset and collected clinical, laboratory, imaging, and 3-month outcome data. NET components [citrullinated histone H3[H3Cit]-DNA complexes and myeloperoxidase (MPO)-DNA complexes, cell-free DNA (cfDNA)] and DNase activity were measured in plasma collected on admission, on day 2/3, and on day 6 (± 1 day) after admission. We assessed ICH volume and perihematomal edema (PHE) semiquantitatively.
resultsWe enrolled 50 patients with ICH (mean age 72 years) with mainly supratentorial ICH (86%), a median ICH volume of 16 ml [interquartile range (IQR) 5.8-38], and a median PHE volume of 11 ml (IQR 5-26). Compared with healthy controls, NETs were detectable in patients with ICH on admission at higher levels (H3Ccit-DNA, p < 0.001; cfDNA, p < 0.001) together with lower DNase activity (p = 0.012). During the first 6 days after ICH, we observed an increase of NET components H3Cit-DNA (baseline, median 6.0 ng/ml [IQR 1.4-9.5] vs. day 6, 12.0 ng/ml [IQR 5.7 vs. 19.0], p < 0.001), MPO-DNA (1.4 ng/ml [IQR 0.59-2.2] vs. 2.6 ng/ml [IQR 1.4-3.4], p < 0.001) and cfDNA (115 ng/ml [IQR 106-125] vs. 137 ng/ml [IQR 127-152], p < 0.001), and a decline in DNase activity (median 85% [IQR 66-102] vs. 66% [IQR 59-80], p < 0.001). NET trajectories correlated with imaging outcomes (ICH volume, PHE volume) and clinical outcome measures.
conclusionsIncreasing NETs and a decrease in DNase activity were observed during the early course after ICH onset and correlated with imaging and clinical outcomes. Future studies should evaluate the functional role of NETs in patients with ICH.
Indexed as
Identifiers
42406306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.